Dyne Therapeutics Quarterly Balance Sheet
NASDAQ: DYNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dyne Therapeutics financial position
As of Jun 30, 2026, Dyne Therapeutics reported total assets of $994.0 million, up 36.4% from a year earlier against total liabilities of $291.9 million. Shareholders' equity stood at $702.2 million, or 70.6% of assets. The company held $676.1 million in cash and equivalents against $199.3 million of debt, a net cash position of $476.8 million.
The current ratio (current assets divided by current liabilities) was 12.02, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.28.
Summary generated from market data by MetaCap's automated system. Methodology
Dyne Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 676.11M | 753.10M | 893.37M | 573.61M | 485.04M | 472.25M | 435.45M | 532.16M | 608.20M | 272.04M | 121.63M | 130.28M |
| Short-Term Investments | 222.36M | 219.05M | 217.19M | 218.28M | 198.88M | 205.24M | 206.82M | 191.51M | 170.64M | 181.51M | 1.47M | 27.54M |
| Total Current Assets | 937.89M | 1.02B | 1.13B | 806.26M | 697.95M | 689.50M | 659.28M | 736.39M | 792.32M | 488.14M | 129.38M | 168.22M |
| Property, Plant & Equipment | 24.56M | 23.68M | 24.03M | 23.97M | 5.67M | 5.75M | 5.40M | 4.90M | 5.02M | 4.58M | 4.78M | 5.11M |
| Total Assets | 994.01M | 1.08B | 1.19B | 867.06M | 728.99M | 721.07M | 691.23M | 768.84M | 825.88M | 522.28M | 165.08M | 205.24M |
| Accounts Payable | 12.15M | 10.78M | 8.08M | 12.06M | 14.02M | 7.02M | 6.56M | 6.16M | 1.89M | 7.21M | 22.94M | 3.55M |
| Total Current Liabilities | 78.03M | 51.25M | 50.63M | 59.85M | 41.47M | 33.88M | 42.26M | 43.26M | 29.75M | 22.36M | 51.09M | 29.69M |
| Long-Term Debt | 199.33M | 149.38M | 148.92M | 99.15M | 98.81M | — | 0 | — | — | — | — | — |
| Total Liabilities | 291.86M | 214.90M | 214.83M | 175.28M | 157.55M | 52.10M | 61.40M | 63.30M | 50.69M | 44.22M | 73.79M | 53.21M |
| Shareholders' Equity | 702.15M | 865.05M | 972.13M | 691.78M | 571.45M | 668.97M | 629.84M | 705.54M | 775.19M | 478.06M | 91.29M | 152.04M |
| Retained Earnings | -1.70B | -1.52B | -1.40B | -1.28B | -1.18B | -1.07B | -949.93M | -860.39M | -763.26M | -698.16M | -632.51M | -565.87M |
| Total Debt | 199.33M | 149.38M | 148.92M | 99.15M | 98.81M | — | 0 | — | — | — | — | — |
| Net Cash (Debt) | 699.15M | 822.78M | 961.64M | 692.74M | 585.11M | 677.49M | 642.27M | 723.67M | 778.84M | 453.55M | 123.10M | 157.82M |
| Shares Outstanding | 165.67M | 165.20M | 164.95M | 142.61M | 114.34M | 113.63M | 102.32M | 101.75M | 100.12M | 87.09M | 61.47M | 61.32M |
This table shows 12 quarterly periods of Dyne Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow DYN's reporting calendar. What is a balance sheet?